Rocket Pharmaceuticals Inc expected to post a loss of 74 cents a share - Earnings Preview

Rocket Pharmaceuticals

06/08/2024 16:11

* Rocket Pharmaceuticals Inc  RCKT.OQ   RCKT.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 4 (estimated) for the period ending September 30 2024
    * The Cranbury New Jersey-based  company is expected to
report
revenue of $1.971 million, according to the mean estimate from
10 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Rocket Pharmaceuticals
Inc is
for a loss of 74 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Rocket
Pharmaceuticals Inc is $47.00​, above​ its last closing price
of $19.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.71       -0.72      -0.74     Missed  -3.2
 Mar. 31 2024  -0.66       -0.68      -0.66     Beat    3.1
 Dec. 31 2023  -0.77       -0.79      -0.64     Beat    18.6​
 Sep. 30 2023  -0.78       -0.81      -0.75     Beat    7.2
 ​​Jan.        -0.79       -0.79      -0.82     Missed  -3.8
 1 0001                                                 
 Mar. 31 2023  -0.86       -0.85      -0.73     Beat    14.3​
 Dec. 31 2022  -0.79       -0.80      -0.92     Missed  -14.6
 Sep. 30 2022  -0.80       -0.79      -0.87     Missed  -10.2
 This summary was machine generated August 6 at 15:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)